Clinical trialsCompany release
Eloxx doses first Alport patients in Phase 2b and wins FDA IND clearance in ADPKD
🇺🇸 Eloxx Pharmaceuticals, Inc. (ELOX) · Mon 16 Nov 2026
Eloxx Pharmaceuticals reported Q3 2026 results, with exaluren now in a Phase 2b Alport trial, an FDA-cleared ADPKD study, and cash guided into 2028.
Eloxx Pharmaceuticals reported its third-quarter 2026 results on 16 November, alongside progress on two clinical programmes for exaluren in rare kidney diseases caused by nonsense mutations.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Eloxx Pharmaceuticals, Inc. ↗
Article written by VigiEye from the official source (Eloxx Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ
🇺🇸 Cerenome, Inc. (CNSY) · Mon 16 Nov 2026
Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial
Clearmind Medicine Inc. (CMND) · Mon 16 Nov 2026
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 16 Nov 2026
CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer
🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026
Aptevo's mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall
🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 16 Nov 2026
Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF
🇺🇸 Rein Therapeutics, Inc. (RNTX) · Mon 16 Nov 2026